The role of ACE2 in the renin-angiotensin-system: Etiology and therapy of COVID-19 from a pharmaceutical perspective.
Pharmazie
; 76(8): 342-350, 2021 08 01.
Article
in English
| MEDLINE | ID: covidwho-1367725
ABSTRACT
Angiotensin-2 converting enzyme (ACE2), a key element of the renin-angiotensin-system (RAS), is not only the direct target of infection by the human SARS-Cov-2 virus but is at the same the root for the complex pathogenetic events of COVID-19. From a pharmaceutical perspective, several established classes of medicines are involved in different phases of the disease. From their known mechanisms of action, a comprehensive understanding of COVID-19 will be hopefully soon delineated. A set of proven medicines is available to cope at least with some of the pathologies involved. To arrive back to normal life, vaccinations and broad consideration of hygienic measures are to be complemented by effective medicines to treat airborne viral infections. Therapeutic schemes based on a comprehensive understanding of the disease will include drug combinations made up from both established drugs as well as novel drugs presently under development.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Renin-Angiotensin System
/
Angiotensin-Converting Enzyme 2
/
COVID-19 Drug Treatment
Type of study:
Etiology study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Pharmazie
Journal subject:
Pharmacy
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS